Sterling steadies vs dollar, euro after profit-taking knock

* Pound edges up vs dollar, flat vs sterling

* Graphic: World FX rates in 2021 Link

* Graphic: Trade-weighted sterling since Brexit vote Link (Updates prices)

By Tom Wilson

LONDON, April 8 (Reuters) - Sterling steadied against the dollar and euro on Thursday, recovering after a bruising bout of profit-taking earlier in the week.

The pound fell 1.2% against the dollar and 1.7% against the euro between Tuesday and Wednesday as investors took cash off the table after a strong first quarter for the British currency.

But by 1500 GMT on Thursday, sterling was up 0.15% against the dollar at $1.3760 GBP=D3 , after touching its lowest this month earlier in the day as the dollar traded near its lowest in two weeks versus major peers.

Against the euro, the pound fell 0.1% to 86.49 pence per euro EURGBP=D3 , following two days of losses against the single currency since September - a fall traders said was amplified by a squeeze of euro-pound short positions.

Traders were largely optimistic over the pound's near-term prospects after a strong start to the year. But some urged caution as markets have already priced in positive news for sterling.

Sterling's pullback was "exaggerated," ING analysts wrote, adding that they were "constructive" on the pound, citing Britain's relatively fast COVID-19 vaccine programme.

Expectations of an economic rebound in Britain, spurred by rapid vaccinations, helped sterling to record its best quarter since 2015 versus the euro. Falling expectations of negative interest rates also helped.

Britain has surged ahead of the rest of Europe in the race to inoculate its population, with almost half of its citizens receiving a first dose. But supply issues from its main Oxford-AstraZeneca AZN.L vaccine have slowed progress in recent days.

Some market players said the pound may struggle to maintain its strong start to the year.

"We are starting what's likely to be much more challenging quarter for sterling," said Adam Cole, chief currency strategist at RBC Capital Markets, with positive news on vaccines and the lower risk of negative rates already priced in.

Others said Britain's economic performance in the next quarter would be a key factor. With infection numbers falling, a planned partial re-opening of the economy is due next week.

"For there to be follow through, we actually need to see the data outperform even expectations," said Stephen Gallo, European head of FX strategy at BMO Capital Markets.
Reporting by Tom Wilson; editing by Mark Heinrich, Chizu Nomiyama, Larry King

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.